Eli Lilly CDR (CAD Hedged)
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study of LY4064809 [14C]-STX-478 in Healthy Male Participants
- Conditions
- Healthy
- Interventions
- Drug: [14C]-STX-478
- First Posted Date
- 2025-03-28
- Last Posted Date
- 2025-04-22
- Target Recruit Count
- 8
- Registration Number
- NCT06901336
- Locations
- 🇺🇸
Pharmaron Clinical Pharmacology Center Inc, Baltimore, Maryland, United States
A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes
- Conditions
- ObesityOverweight
- Interventions
- First Posted Date
- 2025-03-28
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 180
- Registration Number
- NCT06901349
- Locations
- 🇺🇸
Yuma Clinical Trials, Yuma, Arizona, United States
🇺🇸Orange County Research Center, Lake Forest, California, United States
🇺🇸Healthy Brain Clinic, Long Beach, California, United States
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
- First Posted Date
- 2025-03-27
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 240
- Registration Number
- NCT06897475
- Locations
- 🇺🇸
Helios Clinical Research - Phoenix, Phoenix, Arizona, United States
🇺🇸Wolverine Clinical Trials, Tustin, California, United States
🇺🇸Renstar Medical Research, Ocala, Florida, United States
A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2025-03-24
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 100
- Registration Number
- NCT06890611
- Locations
- 🇺🇸
Fortrea Clinical Research Unit, Dallas, Texas, United States
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2025-03-24
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 700
- Registration Number
- NCT06890598
- Locations
- 🇺🇸
Clearview Cancer Institute, Huntsville, Alabama, United States
🇺🇸The University of Arizona Cancer Center - North Campus, Tucson, Arizona, United States
🇺🇸Highlands Oncology Group, Springdale, Arkansas, United States
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
- Conditions
- Chronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2025-03-14
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 279
- Registration Number
- NCT06876662
- Locations
- 🇺🇸
Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸The Emory Clinic, Atlanta, Georgia, United States
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
- Conditions
- Chronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2025-03-14
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 279
- Registration Number
- NCT06876649
- Locations
- 🇺🇸
Swedish Cancer Institute, Seattle, Washington, United States
🇺🇸University of California Medical Center, San Francisco, California, United States
🇺🇸Sylvester Comprehensive Cancer Center, Miami, Florida, United States
A Study of LY3549492 in Japanese Participants With Type 2 Diabetes Mellitus (T2D) and Healthy Japanese Participants
- Conditions
- HealthyType 2 Diabetes Mellitus (T2D)
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-03-11
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 90
- Registration Number
- NCT06869018
- Locations
- 🇯🇵
Medical Corporation Heishinkai OPHAC Hospital, Osaka-shi, Osaka, Japan
🇯🇵P-One Clinic, Hachioji, Tokyo, Japan
🇯🇵Hakata Clinic, Fukuoka, Japan
A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
- First Posted Date
- 2025-03-07
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 200
- Registration Number
- NCT06864026
- Locations
- 🇺🇸
Vida Clinical Research, Kissimmee, Florida, United States
🇺🇸Clinical Research Institute of Michigan, LLC, Saint Clair Shores, Michigan, United States
🇺🇸AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Avondale, Avondale, Arizona, United States
A Study of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis
- First Posted Date
- 2025-03-05
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 40
- Registration Number
- NCT06859294
- Locations
- 🇺🇸
AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Avondale, Avondale, Arizona, United States
🇺🇸AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Flagstaff, Flagstaff, Arizona, United States
🇺🇸AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Phoenix PV, Phoenix, Arizona, United States